{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:54:41Z","timestamp":1793328881076,"version":"4.5.0"},"reference-count":22,"publisher":"Impact Journals, LLC","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,8,15]]},"DOI":"10.18632\/oncotarget.19049","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T01:08:22Z","timestamp":1499389702000},"page":"55094-55103","source":"Crossref","is-referenced-by-count":87,"title":["Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer"],"prefix":"10.18632","volume":"8","author":[{"given":"Florian C.","family":"Gaertner","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Halabi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojjat","family":"Ahmadzadehfar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"K\u00fcrpig","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Eppard","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Kotsikopoulos","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Liakos","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Strunk","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Essler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Zechmann","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer","volume":"56","author":"Eder","year":"2015","journal-title":"J Nucl Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","article-title":"[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer","volume":"42","author":"Haberkorn","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","article-title":"Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer","volume":"69","author":"Babich","year":"2009","journal-title":"Cancer Res"},{"key":"5","first-page":"555","article-title":"Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises","volume":"28","author":"Montironi","year":"2014","journal-title":"J Biol Regul Homeost Agents"},{"key":"6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.115.169243","article-title":"Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer","volume":"57","author":"B\u00f6gemann","year":"2016","journal-title":"J Nucl Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Marx","year":"2017","journal-title":"J Nucl Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.2967\/jnumed.116.173757","article-title":"Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis","volume":"57","author":"Ahmadzadehfar","year":"2016","journal-title":"J Nucl Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/RLU.0000000000001195","article-title":"Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer","volume":"41","author":"Ahmadzadehfar","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/RLU.0000000000001200","article-title":"Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617","volume":"41","author":"Ahmadzadehfar","year":"2016","journal-title":"Clin Nucl Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","author":"Essler","year":"2015","journal-title":"EJNMMI Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Essler","year":"2016","journal-title":"Oncotarget"},{"key":"13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer","volume":"41","author":"B\u00f6gemann","year":"2016","journal-title":"Clin Nucl Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Wesson","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.ijrobp.2009.06.090","article-title":"Radiotherapy dose-volume effects on salivary gland function","volume":"76","author":"Eisbruch","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","author":"Toklu","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"B\u00f6ning","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"18","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Haberkorn","year":"2016","journal-title":"J Nucl Med"},{"key":"19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Wester","year":"2016","journal-title":"J Nucl Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions","volume":"58","author":"Pfob","year":"2017","journal-title":"J Nucl Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11307-016-0942-0","article-title":"Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617","volume":"18","author":"Wild","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2967\/jnumed.113.133041","article-title":"Ethanol-based post-processing of generator-derived 68Ga toward kit-type preparation of 68Ga-radiopharmaceuticals","volume":"55","author":"R\u00f6sch","year":"2014","journal-title":"J Nucl Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:37:40Z","timestamp":1589146660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":22,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2017,8,15]]}},"alternative-id":["19049","28903405"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19049","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]}}}